|
 |
GleevecThis page contains recent news articles, when available, and an overview of Gleevec but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....that will be lost when patents on hypertension drug Diovan and the Gleevec leukemia treatment, the company's best sellers, start to expire in 2012. ... BusinessWeek Gene makeup of cancerous tumors being explored - 06 Jan 2010 Anti-cancer drugs such as tamoxifen and Gleevec have resulted from the genetic research over the last 51 years. Now, however, White, the James and Karen ... Tampa Tribune 诺å?Žå°†ä»¥393äº¿ç¾Žå…ƒä»·æ ¼æ”¶è´çˆ±å°”康剩余股份 - 06 Jan 2010 ...这家制è?¯å…¬å?¸ç›®å‰?æ£ä¾?赖于推出新产å“?æ?¥æŽ¨åŠ¨ä¸šåŠ¡å¢žé•¿ï¼ŒåŽŸå› 是其抗高血压è?¯ç‰©Diovan和销售表现最好的抗白血病è?¯ç‰©Gleevec在美国市场上的专利æ?ƒå°†åœ¨2012年开始到期。 ... 搜狐 Novartis makes both Tasigna and Gleevec. Their motive??? - Dec 10, 2009 Gleevec is THE major advance in hematology in the cast 2 decades. It's track record is without peer and remissions are long lasting. ... Gerson Lehrman Group Synta Pharma starts midstage study of cancer drug - Dec 23, 2009 Synta will study the drug, called STA-9090, in patients who have not responded to treatment with two other cancer drugs, Novartis AG's Gleevec and Pfizer ... BusinessWeek Leukemia: A Home Run and a Long Touchdown Drive - Dec 31, 2009 Leukemia specialists often refer to the emergence of imatinib (Gleevec) for CML as a home run. In contrast, the success story of pediatric ALL might be ... MedPage Today STOCKS NEWS EUROPE-Novartis drops as analysts recommend selling - Dec 10, 2009 ...the loss of about $13 billion gross profit over the next 5-6 years following the genericisation of Gleevec, Diovan, Femara, Zometa and many others." Reuters Synta Pharma initiates phase 2 trial of STA-9090 in gastrointestinal stromal ... - Dec 29, 2009 ..."Both imatinib (Gleevec) and sunitinib (Sutent) have proven very effective in helping patients with GIST to live longer; however, the majority of patients ... pharmabiz.com Top Five Biotech Innovations of the 2000s - Dec 30, 2009 Novartis' imatinib (Gleevec)—An effective and safe treatment for various leukemia syndromes, saving countless lives. It set off massive searches in the ... Xconomy Top Five Medical Innovations of the 2000s (And One Big Concern) - Dec 29, 2009 Novartis' imatinib (Gleevec) is the poster child for this. 3—Sequencing the human genome, and rapidly expanding the technology to allow the analysis of ... Xconomy A Battle Close To Home: Thirty Eight Years After Nixon's Declaration Of War - Dec 14, 2009 At the turn of this century, newspapers and magazines heralded the advent of targeted therapies Herceptin and Gleevec as evidence that cancer would be ... Huffington Post (blog) ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML - Dec 13, 2009 At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed ... PipelineReview.com (press release) Aussie pharmaceutical company signs deal with US outfit - Dec 14, 2009 Omapro, also called omacetaxine mepesuccinate, is targeted at patients with a genetic mutation that makes them resistant to Novartis's Gleevec. ... The Australian Sprycel® and Chemotherapy Effective for Ph+ ALL - Dec 10, 2009 ...[1] Sprycel is a newly developed tyrosine kinase inhibitor that is 325-fold more active than Gleevec® (imatinib) for inhibition of Bcr-Abl. Sprycel is ... Cancer Consultants How Much To Extend Life? Allos Therapeutics Says $30000 per Month - Dec 14, 2009 Gleevec (imatinib), which is used both on and off-label for a variety of blood cancers, costs roughly $92000 per year for a 400 mg/day dose. ... BNET Hear It Here First!! ZVTK "Zevotek Announces Ionic Bulb TV Ads to Air Starting ... - Dec 23, 2009 Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec(R) and Sutent(R) ... TMCnet Novartis May Sell Bonds in 2010 for $28.2 Billion Alcon Deal - Dec 30, 2009 ...used in eye surgery as patents on the hypertension drug Diovan and the Gleevec cancer medicine, its best sellers, start to expire in the US in 2012. ... BusinessWeek Changing therapy from Glivec(R) to a "copy"imatinib results in a worsening of ... - Dec 17, 2009 IntroductionImatinib mesylate (Glivec(R)/Gleevec(R)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high ... 7thSpace Interactive (press release) Novartis Shifts Focus to Rare Diseases - Dec 20, 2009 Novartis is now one of the world's biggest drug companies, known for multibillion-dollar drugs such as Diovan for blood pressure and Gleevec for cancer. ... Wall Street Journal New Inhaled Insulin, Provenge, Top List of 2010 Action Dates - Dec 31, 2009 ...in adults with chronic leukemia who have failed prior therapy with Gleevec (imatinib, Novartis AG) and who have developed the Bcr-Abl T315I mutation. ... BioWorld Online Anthony Pawson - Jan 1, 2010 By unravelling the language of cells, and specific proteins within cells, Dr. Pawson has paved the way for others to develop drugs like Gleevec, ... Globe and Mail Decade of science highs and lows - Dec 18, 2009 Targeted cancer therapy: The Food and Drug Administration approves imatinib, marketed under the name Gleevec, as the first in a class of drugs that target ... msnbc.com Danusertib, a Multi-Kinase Aurora Inhibitor, Promising for Treatment of CML ... - Dec 28, 2009 ...positive (Ph+) acute lymphoblastic leukemia (ALL) who have failed treatment with Gleevec® (imatinib), Sprycel® (dasatinib), and Tasigna® (nilotinib). ... Cancer Consultants Rough year for cancer journals - Dec 29, 2009 Indeed, during the first part of this decade, the FDA approved drugs that changed cancer treatment, such as Avastin, Tarceva and Gleevec. ... Medical Marketing and Media Oncology R&D Challenges & Opportunities - Dec 29, 2009 Paradigm-changing drugs like Gleevec, with cure rates approaching 95% in patients with chronic myeloid leukemia, tend to heighten regulatory expectations. ... Life Science Leader Magazine EpiCept Provides Clinical and Business Update on Ceplene Program - Dec 15, 2009 The primary objective of the study will be to assess the safety of the combination therapy of Ceplene/IL-2 with Gleevec given for six months and to assess ... PharmaLive.com (press release) Bone Drugs Linked to Fewer Cases of Breast Cancer - Dec 15, 2009 Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic ... NCI Cancer Bulletin Coverage of Orally Delivered Oncology Drugs to Shift More Cost Responsibility ... - Dec 14, 2009 Orally delivered agents for hematogical cancers include Novartis' Gleevec, Celgene's Revlimid and Bristol-Myers Squibb's Sprycel. ... PR Newswire (press release) Cancer Drug Could Potentially Treat Scleroderma - Dec 15, 2009 ...at the annual meeting of the American College of Rheumatology, 30 patients with diffuse scleroderma were recruited and given 400mg of Gleevec per day. ... American Journal of Hemotology and Oncology Research Oracle roundup for 14 December 2009 - Dec 14, 2009 ...launch of Tasigna as a first line treatment early next year will recover some of the expected revenue loss from the launch of Gleevec generics in 2012. ... Research Oracle (blog) Research Oracle roundup for 11 December 2009 - Dec 11, 2009 ...launch of Tasigna as a first line treatment early next year will recover some of the expected revenue loss from the launch of Gleevec generics in 2012. ... Research Oracle (blog) Chicago Cancer Genome Project Studies Genetics of 1000 Tumors - Dec 29, 2009 ...and Janet Rowley's descriptions of the first chromosomal translocations in 1972, work that led to the targeted therapy known as Gleevec. ... ADMET.net Novartis: akwizycja warta 39,3 mld dol. - Jan 4, 2010 ...kiedy wygasnÄ… patenty w Stanach Zjednoczonych na najlepiej sprzedajÄ…ce siÄ™ leki: Diovan (na nadciÅ›nienie) i Gleevec (przeciw biaÅ‚aczce). ... Rzeczpospolita Στη Novartis το 52% της Alcon Îναντι 28,1 δισ. δολ. - Jan 5, 2010 τα Îσοδα της οποίας απειλοÏ?νται καθώς οι πατÎντες των δÏ?ο κοÏ?υφαίων σε πωλήσεις φαÏ?μάκων της -Diovan και Gleevec- εκπνÎουν στις ΗΠΑ το 2012 και το 2015. ... Ελευθεροτυπία Novartis pone la mira en Alcon, lÃder en tratamientos oftalmológicos - Jan 4, 2010 ...considerando que las patentes de sus superventas como el Diovan para la hipertensión o el Gleevec para la leucemia, expirarán en Estados Unidos hacia ... euronews Novartis absorbera l'intégralité d'Alcon - Jan 4, 2010 ...médicaments arrivant prochainement à échéance (dont les gros vendeurs que sont le Diovan contre l'hypertension, et le Gleevec contre la leucémie), ... Le Temps (Abonnement) Óriási terjeszkedés - a Novartis szemet vetett az Alconra - Jan 4, 2010 2012-ig elveszÃti a legkelendÅ‘bb gyógyszerek közé számÃtó Diovan vérnyomáscsökkentÅ‘ készÃtmény és a leukémia kezelésére használt Gleevec szabadalmát. Gazdasági Rádió Prvý veľký obchod roka: Novartis prevezme Alcon - Jan 4, 2010 ...produkty ako liek Diovan proti vysokému krvnému tlaku a Gleevec na lieÄ?bu pacientov s leukémiou stratia v roku 2012 v Spojených Å¡tátoch platnosÅ¥. ... HNonline.sk RECHERCHE RAPIDE PAR ORGANISME - Dec 10, 2009 Les comprimés de Gleevec* sont le traitement de référence établi de cette maladie. Dans le cadre de la comparaison parallèle de deux traitements initiaux, ... CNW Telbec (Communiqué de presse) èƒƒè‚ é?“间质瘤新è?¯STA-9090进入Ⅱ期临床实验 - Dec 27, 2009 ...这次属于éš?机ã€?æ ‡ç¾å¼€æ”¾ã€?多ä¸å¿ƒä¸´åºŠå®žéªŒï¼Œä¸»è¦?检测STA-9090的疗效和安全性，å?—试者主è¦?为转移性或ä¸?宜进行手术切除的GIST患者，他们å?‡é‡‡ç”¨è¿‡Gleevecå’ŒSutent进行过 ... 药通天下网 Laboratorio Novartis venderá bonos para aumentar participación en Alcon - Jan 1, 2010 ...ojos en tanto las patentes de sus fármacos Diovan, contra la hipertensión, y Gleevec, contra el cáncer, empiezan a expirar en Estados Unidos en el 2012. latercera.com Novartis "hold" - Dec 10, 2009 Dennoch glaube man bei der Société Générale, dass eine Umstellung von "Gleevec" zu "Tasigna" weiterhin schwierig sei. Mit "Tasigna" könne Novartis das ... newratings.de Chữa bệnh theo đặc tÃnh gen - Dec 12, 2009 ChÃnh nhá»? sá»± phân loại đối tượng bệnh nhân dá»±a trên cÆ¡ sở di truyá»?n, mà các loại biệt dược chống ung thÆ° nhÆ° Gleevec của Novartis hay Tarceva của ... Báo Khoa học Ricerca: sette progetti per provare a curare e prevenire il mesotelioma - Dec 11, 2009 In corso di valutazione sono invece i dati del trial di Gleevec e Gem che è servito se non altro a mettere a fuoco alcune problematiche relativamente alla ... Il Monferrato Leukemia treatment drug Gleevec produced by the Swiss Novartis … - Jul 24, 2006 BEIJING, July 24(Xinhuanet) -- Leukemia treatment drug Gleevec produced by the Swiss Novartis Pharmaceuticals may lead to severe heart damage, ... æ–°å?Žç½‘ Cancer Drug Gleevec Could Fight Stroke - Jun 23, 2008 By Ed Edelson. MONDAY, June 23 (HealthDay News) -- A powerful weapon against cancer might also boost stroke patients' survival, new research suggests. ... Washington Post New Drugs May Challenge Novartis' Gleevec - Dec 10, 2005 By Althea Chang 12/10/05 - 04:13 PM EST. ATLANTA -- Newer, more potent leukemia treatments could eventually replace Novartis' (NVS Quote) Gleevec, ... TheStreet.com - TheStreet.com (subscription) Gleevec keeps stomach tumor at bay: study - Apr 12, 2007 WASHINGTON (Reuters) - Gleevec, a once-a-day pill that has helped boost the survival rate for some leukemia patients, lowers the risk that a rare stomach ... Reuters Reworked Gleevec curbs heart-related complication - Dec 3, 2007 By Will Dunham. WASHINGTON, Dec 3 (Reuters) - A redesigned version of Novartis AG's (NOVN.VX) cancer drug Gleevec may avoid a rare heart-related side effect ... Reuters Cancer drug Gleevec may damage heart: study - Jul 23, 2006 By Maggie Fox, Health and Science Correspondent | July 23, 2006. WASHINGTON (Reuters) - Gleevec, the pill that transformed cancer treatments by offering an ... Boston Globe Gleevec Given Priority FDA Review for Intestinal Cancer - Aug 27, 2008 The US Food and Drug Administration has given priority review to the Novartis drug Gleevec (imatinib mesylate) as a treatment for gastrointestinal cancer ... ABC News Novartis' Gleevec wins US approval for five rare diseases - Oct 20, 2006 EAST HANOVER, NJ (AFX) - Novartis AG said it has won US permission to market the cancer drug Gleevec for treating five rare and potentially life-threatening ... Forbes Novartis' Gleevec Approved for Recurrence of Tumors - Dec 19, 2008 By David Olmos. Dec. 19 (Bloomberg) -- Novartis AG said its best-selling cancer drug Gleevec won US approval to slow the recurrence of a rare ... Bloomberg Gleevec Pushes Advanced Melanoma Into Remission - Apr 18, 2008 THURSDAY, April 17 (HealthDay News) -- The cancer drug Gleevec has forced metastatic melanoma into remission for the first time, report researchers at the ... Washington Post Gleevec effective against leukemia. - Dec 10, 2007 ATLANTA, Dec. 10 (UPI) -- The drug Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic ... United Press International Gleevec Pushes Advanced Melanoma Into Remission - Apr 17, 2008 By Robert Preidt. THURSDAY, April 17 (HealthDay News) -- The cancer drug Gleevec has forced metastatic melanoma into remission for the first time, ... ABC News Bristol cancer drug could compete with Novartis' Gleevec - Jun. 1,... - Jun 1, 2006 By Aaron Smith, CNNMoney.com staff writer. NEW YORK (CNNMoney.com) - Right now it's an experimental cancer drug about to get a thumbs up from the FDA for ... CNNMoney.com Bristol, Novartis Bid to Replace Gleevec for Leukemia - Dec 10, 2007 By Luke Timmerman. Dec. 10 (Bloomberg) -- Drugs from Bristol-Myers Squibb Co. and Novartis AG helped leukemia patients remain free of cancer for a year in ... Bloomberg Slowly, Cancer Genes Tender Their Secrets - Dec 27, 2005 Gleevec, researchers say, was the first test of this idea. ... But the clinical trial of Gleevec, conducted at the Oregon Health & Science University, ... New York Times 5 Years Later, Gleevec Fights Cancer - Dec 6, 2006 By Salynn Boyles. Dec. 6, 2006 -- When first introduced in 2001, Gleevec was hailed as a miracle drug poised to usher in a new age in cancer treatment. ... WebMD Novartis's Gleevec Patent Challenge Rejected in India - Aug 6, 2007 By Eva von Schaper. Aug. 6 (Bloomberg) -- Novartis AG said its challenge to Indian patent law over the country's rejection of a patent on the best-selling ... Bloomberg Study shows new drug delays intestinal cancer - Nov 3, 2005 The prognosis of this cancer had been dire until the targeted drug Gleevec, or imatinib, came along about five years ago. However, Gleevec stops working for ... USA Today New cancer drug approved - Jan 26, 2006 Gleevec was one of the first drugs designed to disable specific growth ... About half of GIST patients develop resistance to Gleevec in only about two years ... USA Today Better Weapons in the Cancer War - May 16, 2005 Though there are still only a handful of such drugs on the market so far, among them Genentech's (DNA ) Avastin and Tarceva, Novartis' (NVS ) Gleevec, ... BusinessWeek Gleevec prevents GIST cancer return - Jun 5, 2007 CHICAGO, June 5 (UPI) -- Adding Gleevec after surgery for gastrointestinal stromal tumors prevents return of cancer in more than 90 percent of patients, ... United Press International Leukemia pill may improve stroke treatment: study - Jun 22, 2008 Studies in mice showed giving Gleevec or imatinib, a drug made by ... Gleevec, which blocks the PDGF-alpha receptor, appears to counteract this effect. ... Reuters Study shows patients on Gleevec improve - Also, a sexually transmitted... - Jun 5, 2006 The targeted cancer therapy Gleevec created a stir five years ago with stunning results for patients with chronic myeloid leukemia. ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic … - Dec 12, 2005 ...- For the first time, a separate retrospective comparison shows significant improvement in survival for Gleevec vs. historical interferon-based treatment ... Free with registration - PR Newswire - AccessMyLibrary.com CORRECTED - US OKs Novartis Gleevec to reduce recurring cancer - Dec 20, 2008 WASHINGTON, Dec 19 (Reuters) - US health regulators have approved Novartis' (NOVN.VX: Quote, Profile, Research) drug Gleevec to reduce the risk of cancer ... Reuters India Novartis Profit Rises 4.1% on Diovan, Gleevec Sales - Jul 17, 2006 By Carey Sargent. July 17 (Bloomberg) -- Novartis AG, Europe's third-largest drugmaker, said second-quarter profit rose 4.1 percent as sales of the heart ... Bloomberg Use Two Drugs at Once to Beat Leukemia: Study - Aug 16, 2007 Normally, CML patients are first treated with Gleevec. If the cancer develops resistance to Gleevec and returns, it's treated with Sprycel. ... Washington Post Drugmakers Focus on Cancer Cures - Mar 17, 2005 Novartis SA's Gleevec, introduced in 2001, treats a form of leukemia (search) as well as ... "Look at Erbitux and Gleevec. They may be for small markets, ... FOXNews New hope in fight against deadly cancers - Sep 4, 2008 Although genetic understanding already underpins the latest generation of anti-cancer drugs, such as Gleevec, it mostly concerns simple genetic changes. ... Telegraph.co.uk Gleevec Continues to Beat Blood Cancer - Dec 6, 2006 By EJ Mundell. WEDNESDAY, Dec. 6 (HealthDay News) -- Doug Jenson, a 73-year-old retiree in Canby, Ore., knows what the "wonder drug" Gleevec has given him. ... Washington Post … Leukemia - Next-era targeted therapy overcoming Gleevec's … - Apr 20, 2005 Though Gleevec has shown "wonder drug" capabilities for treating chronic ... As originally conceived, Gleevec works in CML patients by selectively ... Medical News Today - Medical News Today (press release) Sprycel said to work as 1st treatment in blood cancer - Jun 2, 2007 More tests are needed to show if Sprycel should be given first, keeping Gleevec as a back-up if the cancer, a type known as chronic myelogenous leukemia or ... Reuters UK The Maker of a Miracle Drug - Dec 24, 2008 The result was the miracle drug Gleevec. Now, Druker hopes to build on his success ... An advance like Gleevec "only comes along once in 10 lifetimes," says ... BusinessWeek Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors - Apr 16, 2007 The US-based National Cancer Institute (NCI) has commended Novartis' anti-cancer tablet, Gleevec, as an effective therapy for patients suffering from GISTs, ... MedIndia Pfizer Positive on Sutent | Biotech/Pharmaceuticals | Financial... - May 14, 2005 The results from a Phase III study of more than 300 GIST patients resistant to or intolerant of the standard treatment Gleevec, showed Sutent prolonged the ... TheStreet.com - TheStreet.com (subscription) Cancer Drugs May Treat Type 1 Diabetes - Nov 17, 2008 In experiments with mice, they found that Gleevec and a similar cancer drug, ... "Although targeted to the Bcr-Abl kinase, Gleevec has been shown to affect ... Forbes … Battles Resistance To Leukemia Pill Gleevec 'Extremely Effective'... - Jun 15, 2006 ScienceDaily (June 15, 2006) — An experimental therapy that battles drug resistance in Chronic Myeloid Leukemia (CML) has proved "extremely effective" in ... sciencedaily.com Sprycel works as 1st treatment in blood cancer - Jun 3, 2007 More tests are needed to show if Sprycel should be given first, keeping Gleevec as a back-up if the cancer, a type known as chronic myelogenous leukemia or ... Reuters India Pfizer Gains on Test Data | Biotech/Pharmaceuticals | Financial... - Feb 8, 2005 Gleevec is a cancer drug sold by Novartis(NVS Quote). "Pfizer and study investigators are working together to provide SU11248 to those enrolled in the study ... TheStreet.com - TheStreet.com (subscription) Weighing Costs in Choosing Cancer Care - Mar 25, 2008 But few patients get a Gleevec-style home run, and there's very little research that directly compares competing treatments to guide cancer patients on ... FOXNews Cancer drug may decrease heart function, company advises - Oct 2, 2006 The cancer drug Gleevec may carry a risk for decreased heart function, ... Gleevec or imatinib mesylate is used to treat adults with a type of blood cancer ... CBC.ca Targeted drug combos could outsmart cancer - Sep 13, 2007 When they tried Gleevec, known generically as imatinib, it had little effect on the cells. But when they combined it with two other drugs -- Tarceva, ... Reuters Cancer Drugs Offer Hope, but at a Huge Expense - Jul 12, 2005 Gleevec. Herceptin. Rituxan. Tarceva. These are among the first in a wave of new ... And except for Gleevec, a leukemia drug from Novartis that has produced ... New York Times Infinity, Astra Feel Need For Speed - May 31, 2008 But the average GIST tumor becomes resistant to Gleevec in 18 months, ... There is potential that later on IPI-504 might be combined with Gleevec or Sutent ... Forbes FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec - Jun 29, 2006 By Peggy Peck, Managing Editor, MedPage Today. ROCKVILLE, Md., June 29 — The FDA today granted accelerated approval to Sprycel (dasatinib) for adults with ... MedPage Today FDA OKs Novartis Leukemia Drug For Patients Resistant to Gleevec - Oct 29, 2007 By JENNIFER CORBETT DOOREN and JEANNE WHALEN. The Food and Drug Administration approved a new drug from Novartis AG to treat patients with a form of ... Subscription - Wall Street Journal Online - Dow Jones & Company Novartis Hedges Its Bets - Sep 23, 2005 One of Novartis' more promising cancer drugs is AMN107 for chronic myeloid leukemia, a successor to the firms' breakthrough drug, Gleevec. ... Forbes Gleevec May Disrupt Ovarian Function - Mar 5, 2008 By Serena Gordon. WEDNESDAY, March 5 (HealthDay News) -- Although it's a much more targeted treatment than standard chemotherapy, the effective and ... HealthCentral.com Betting on a new cancer drug - Jun 16, 2006 Kevin Williams had taken the breakthrough cancer drug Gleevec for more than two years, ... Trials are already under way to test the drug against Gleevec. ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette Doctors may have hit upon 'holy grail' of cancer therapy - Jul 13, 2007 Those in one group received Gleevec at a dose of 400 milligrams per day for one year ... In comparison, 83 percent of patients who did not take Gleevec were ... Bizjournals.com Gleevec Approved As First Treatment To Reduce Returning Cancer Risk - Dec 20, 2008 Novartis announced today that Gleevec (imatinib mesylate) tablets has been approved by the US Food and Drug Administration (FDA) for the post-surgery ... emaxhealth.com SGX, Novartis Sign $515M Deal - Mar 27, 2006 Novartis won approval for Gleevec in May 2001 after only two and half months. However, Novartis's patent has been under challenge from generic drug makers, ... Red Herring Increasing benefit seen in novel drug AMN107, that treats Gleevec … - Apr 23, 2005 ...“Gleevec is incredibly powerful and failures are very rare in early phase CML. ... Gleevec binds to this Bcr-Abl enzyme, shutting down its activity, ... News-Medical.net Novartis goes to court in India over Gleevec. - swissinfo - Jan 29, 2007 A court case brought by Swiss drugs giant Novartis in India could define how the industry distributes discount medicine to the developing world while ... radio rottu oberwallis Approach enlists immune system to fight leukemia - Jun 20, 2008 ..."The hope really is to get patients off Gleevec ultimately," said Dr. Peter Lee of Stanford ... Gleevec, or imatinib, a once-a-day pill made by Novartis, ... Reuters UK Five Years After Approval, Gleevec Underscores The Promise Of … - May 12, 2006 Marking an important milestone since its first approval in May 2001, Gleevec(R) (imatinib mesylate) tablets,* has become the first oncology drug to be ... Medical News Today - Medical News Today (press release) Approach enlists immune system to fight leukemia - Jun 19, 2008 ..."The hope really is to get patients off Gleevec ultimately," said Dr. Peter Lee of Stanford ... Gleevec, or imatinib, a once-a-day pill made by Novartis, ... Reuters New Cancer Drug Tied to Heart Problems - Dec 14, 2007 Other drugs in this family include imatinib, better known as Gleevec, and dasatinib (Sprycel). In the study, which is published in the Dec. ... Washington Post Gleevec casts a pox on poxviruses - Jul 1, 2005 The author is at the University of Western Ontario and the Robarts Research Institute, London, Ontario, N6G 2V4, Canada. mcfadden@robarts.ca ... Nature.com Sprycel® Superior to High-Dose Gleevec for Gleevec-Resistant CML - Dec 9, 2006 Researchers affiliated with the START-R randomized trial presented data suggesting that Sprycel (dasatinib) was more effective than escalated doses of ... Cancer Consultants … That Battles Resistance to Leukemia Pill Gleevec 'Extremely... - Jun 14, 2006 LOS ANGELES, June 14 (AScribe Newswire) -- An experimental therapy that battles drug resistance in Chronic Myeloid Leukemia (CML) has proved "extremely ... Free with registration - AScribe Medicine News Service - AccessMyLibrary.com Figure - Nature Cell Biology - Jul 23, 2006 The difference between Fc plus Gleevec or ephrin-B2 Fc plus Gleevec and Fc is not significant. (d, e) Body weights were measured at day 14 (U, ... Nature.com Cancer Drug for Rheumatoid Arthritis? - Sep 14, 2006 A new study shows the cancer drug Gleevec blocked the progression and ... Gleevec is a cancer drug often used to treat leukemialeukemia and some types of ... WebMD Futile care for dying cancer patients on rise - Jun 3, 2006 This study focused on traditional chemotherapy and was done before newer medicines such as Herceptin, Avastin, and Gleevec, which more precisely target ... Boston Globe ChemGenex Investigators Report Activity of Omacetaxine in Imatinib- … - Dec 10, 2007 Gleevec(R)/Glivec(R) is a registered trade-mark of Novartis AG. About ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com) ChemGenex Pharmaceuticals ... Reuters UK Novartis: do Indian patent laws stifle research? - Aug 9, 2007 The Novartis case (the patent application for its anti-cancer drug Gleevec) had many firsts to its credit. It signified the first instance of grant of a ... Hindu Bristol-Myers Squibb reports positive results from SPRYCEL trials … - Dec 11, 2006 ...'These data show that many patients who were resistant or intolerant to (leukaemia drug) Gleevec responded to a once a day dose of SPRYCEL with an improved ... Forbes Medical Aid Groups Welcome Indian Court Ruling on Medicine Patents - Aug 12, 2007 Novartis had filed suit after its bid to patent a new version of its anti-cancer drug, Gleevec, was rejected earlier this year. Indian law denies patents ... Voice of America Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia … - Jun 3, 2006 EAST HANOVER, NJ, June 3 /PRNewswire/ -- Response rates to Gleevec(R) (imatinib mesylate)* tablets continue to increase substantially over time while the ... Free with registration - PR Newswire - AccessMyLibrary.com Sun Pharma to market Gleevec's generic version - Aug 26, 2006 MUMBAI: The $2.2 billion anti-cancer drug Gleevec, is about to face stiff ... Novartis, owner of Gleevec, will soon have to contend with Indian generic ... Times of India MEDICINE / IN THE LAB; Moles' split personality; One mole stays... - Apr 28, 2008 The drug, imatinib, is currently manufactured by Basel, Switzerland-based Novartis International AG under the trade name Gleevec and is used to treat ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Novartis profit climbs 23% on blood pressure, cancer drugs - … - Jan 18, 2007 During the quarter, sales of hypertension drug Diovan rose 16% to $1.15 billion and sales of Gleevec, a leukemia drug, rose 19% to $702 million. ... MarketWatch Novartis Profit Rises 11% on Diovan, Gleevec Sales - Apr 23, 2007 By Eva von Schaper. April 23 (Bloomberg) -- Novartis AG, Europe's third-largest drugmaker, said first-quarter profit rose as the company paid less than ... Bloomberg Sales Advance at Novartis - Jan 19, 2006 Net sales in the US climbed 14% to $2.2 billion, fueled by growth in the drugs Diovan, Lotrel, Gleevec, Femara and Zelnorm. In Europe, net sales fell 2% in ... TheStreet.com - TheStreet.com (subscription) CML factbox - Oct 9, 2007 Gleevec, which a source says is the drug Jason Blake is taking, inhibits the overproduction of white cells and assists the production of red cells. ... Globe and Mail Médecins Sans Frontières International Homepage - Feb 16, 2007 Novartis has been refused a patent for a cancer medicine, Gleevec, on the grounds ... In other countries where Novartis has obtained a patent for Gleevec, ... Medecins Sans Frontieres - Medecins Sans Frontieres The Race Is On - Jul 3, 2006 Both hit all but one of dozens of Gleevec-resistant strains in the test tube, ... CML is fueled by a defective protein called Bcr-Abl. Gleevec blocks this ... Forbes Broken Stress Response System Can Contribute to Gleevec Resistance - Apr 20, 2006 CHEVY CHASE, MD -- April 20, 2006 -- New clues to why some kinds of leukemia are more aggressive and deadly than others are coming from research examining ... DG News Next-era targeted therapy overcoming Gleevec's shortcomings - Apr 8, 2005 Though Gleevec has shown "wonder drug" capabilities for treating chronic ... As originally conceived, Gleevec works in CML patients by selectively ... PsychCentral.com SGX to collaborate on leukemia drug. - Mar 29, 2006 Gleevec is a blockbuster drug Novartis developed for the treatment of chronic ... Since it was approved for market in 2001, Gleevec has become the standard ... Free with registration - San Diego Union - Tribune - AccessMyLibrary.com Novartis Posts Record Earnings for 10th Year - Jan 19, 2007 Gleevec was second with sales of $2.5 billion. The sharpest increase was recorded in its Sandoz generic drugs unit, where sales increased by 27 percent to ... New York Times Africa: Generic Medicines Walk the Plank - Mar 6, 2007 Novartis wants patent protection for its leukaemia drug, Gleevec. ... As a result, Gleevec could not be patented under Indian law, but the claim Novartis ... AllAfrica.com Novartis Delivers Strong Start to 2006 in First Quarter with Excellent... - Apr 24, 2006 In oncology, our breakthrough medicine Gleevec/Glivec was submitted in the US and Europe for approval for the treatment of four rare types of cancer, ... primezone.com Shooter will carry Scottish flag - Mar 13, 2006 In 2001, he took part in clinical trials for a new drug, Gleevec, ... "I took part in a clinical trial in 2001 for Gleevec and it's thanks to that that I'm ... BBC News He Won His Battle With Cancer - Sep 4, 2008 Gleevec, for instance, treats one form of leukemia by zeroing in on the Philadelphia ... Because of drugs like Gleevec and therapies such as bone-marrow and ... TIME Gleevec reduces recurrence in colon cancer - Apr 13, 2007 New York – April 13, 2007 – Patients with a type of colon cancer who received the "leukemia pill" Gleevec® after complete removal of their tumors were ... Cancerfacts.com … Report Activity of Ceflatonin(R) and Gleevec(R) Combination... - Dec 10, 2006 The presentation described the effects of the Ceflatonin® and Gleevec® combination therapy on CML ... Gleevec® is a registered trade-mark of Novartis AG. ... cbs5.com Blake will rely on wonder drug; Gleevec gives victims of CML a good … - Oct 10, 2007 ..."It has dramatically changed treatment for this disease," Dwayne Barber, a senior scientist at the Ontario Cancer Institute, said of the medication, ... Pay-Per-View - Toronto Star - ProQuest Archiver Small heart risk traced in cancer drug. | Article from Philadelphia... - Jul 24, 2006 And implications of the research may extend beyond Gleevec, revealing potential ... But scientists did not know why Gleevec had caused the heart to fail. ... Pay-Per-View - Philadelphia Inquirer - HighBeam Research Genzyme Launches Key Test to Monitor Gleevec(R) Resistance - Feb 9, 2006 CAMBRIDGE, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Genzyme Corporation announced today the availability of an important new test to monitor drug resistance ... RedOrbit 'Don't force us to issue compulsory licence on Gleevec' - Apr 11, 2007 New Delhi, Apr 10: In a veiled threat to Swiss pharmaceutical major Novartis to withdraw the case the company had filed after being denied patent on its ... Financial Express A Broken Stress Response System Can Contribute To Gleevec … - Apr 24, 2006 New clues to why some kinds of leukemia are more aggressive and deadly than others are coming from research examining the types of genetic damage that allow ... Medical News Today - Medical News Today (press release) Novartis Expects December Action on Gleevec Priority Review - Sep 3, 2008 Novartis expects the FDA to make a decision in December on the use of its kinase inhibitor Gleevec as a first-line treatment after surgery for ... FDA news - FDA news (subscription) Novartis Strikes Deal With Thailand Over Gleevec - Jan 31, 2008 By Ed Silverman // January 31st, 2008 // 3:36 pm. As a result, Thailand's public health minister, Mongkol na Songkhla, cancelled a compulsory license for ... Pharmalot New Drug Duo Helps Cut Colon Cancer Risk - Apr 14, 2008 Sutent, a member of a family of cancer drugs that also includes Gleevec (imatinib), has proven effective against kidney cancer and a type of malignancy ... Washington Post FDA approves new leukemia treatment dasatinib (Sprycel) - Jun 30, 2006 This new leukemia treatment is a targeted therapy that may give hope to people for whom imatinib (Gleevec) no longer works or for those who never had ... CNN International Adjuvant Gleevec® May Prevent Recurrences in Resected GIST - Jun 1, 2007 Researchers involved in a North American Intergroup Phase III trial (ACOSOG Z9001) have reported that the adjuvant administration of Gleevec (imatinib) may ... Cancer Consultants … Completes Submissions in US and Europe for Gleevec(R) As Treatment... - Apr 10, 2006 EAST HANOVER, NJ, April 10 /PRNewswire/ -- Novartis announced today that it has submitted applications in the United States and Europe for Gleevec(R) ... RedOrbit Patent trouble - Feb 10, 2007 Second, Novartis has secured access to Gleevec in India and globally: "In ... In India, 99 per cent of patients who receive Gleevec receive it free from ... The Hindu New drug showing promise. - Jan 31, 2006 She had stopped responding to standard treatment with the drug Gleevec and was ... Although Gleevec offers significant improvements for many patients, ... Free with registration - Fort Worth Star-Telegram - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |